ATE275642T1 - Verfahren zur diagnose von krebs - Google Patents

Verfahren zur diagnose von krebs

Info

Publication number
ATE275642T1
ATE275642T1 AT01928158T AT01928158T ATE275642T1 AT E275642 T1 ATE275642 T1 AT E275642T1 AT 01928158 T AT01928158 T AT 01928158T AT 01928158 T AT01928158 T AT 01928158T AT E275642 T1 ATE275642 T1 AT E275642T1
Authority
AT
Austria
Prior art keywords
diagnosis
cancer
cancers
diagnosing
rna
Prior art date
Application number
AT01928158T
Other languages
English (en)
Inventor
Xu Qi Chen
Maurice Stroun
Philippe Anker
Original Assignee
Chen Xu Qi University Of Teaxs
Maurice Stroun
Philippe Anker
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8168848&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE275642(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chen Xu Qi University Of Teaxs, Maurice Stroun, Philippe Anker filed Critical Chen Xu Qi University Of Teaxs
Application granted granted Critical
Publication of ATE275642T1 publication Critical patent/ATE275642T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
AT01928158T 2000-05-26 2001-05-16 Verfahren zur diagnose von krebs ATE275642T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00111370A EP1158055A1 (de) 2000-05-26 2000-05-26 Verfahren zur Diagnose von Krebs
PCT/IB2001/000852 WO2001090409A1 (fr) 2000-05-26 2001-05-16 Methode pour le diagnostic de cancers

Publications (1)

Publication Number Publication Date
ATE275642T1 true ATE275642T1 (de) 2004-09-15

Family

ID=8168848

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01928158T ATE275642T1 (de) 2000-05-26 2001-05-16 Verfahren zur diagnose von krebs

Country Status (8)

Country Link
US (1) US7163789B2 (de)
EP (2) EP1158055A1 (de)
AT (1) ATE275642T1 (de)
AU (1) AU5502101A (de)
DE (1) DE60105411T2 (de)
ES (1) ES2227178T3 (de)
PT (1) PT1283907E (de)
WO (1) WO2001090409A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6607898B1 (en) 1996-03-26 2003-08-19 Oncomedx, Inc. Method for detection of hTR and hTERT telomerase-associated RNA in plasma or serum
US20030158673A1 (en) * 2002-02-16 2003-08-21 Ingene Institut Fur Genetische Medizin Gmbh Method for creating a blood bank with associated data bank
ITMI20022743A1 (it) 2002-12-23 2004-06-24 Ist Naz Stud Cura Dei Tumori Metodo per la determinazione del rischio di comparsa, della presenza o del decorso di malattie tumorali.
EP1528107B1 (de) * 2003-10-29 2006-11-22 Maurice Stroun Verfahren zur Diagnose von Krebs
EP1712639B1 (de) 2005-04-06 2008-08-27 Maurice Stroun Methode zur Krebsdiagnose mittels Nachweis von DNA und RNA im Kreislauf
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
CN103424541B (zh) 2006-05-18 2018-01-30 分子压型学会股份有限公司 确定针对病状的个性化医疗介入的系统和方法
US8252528B2 (en) * 2008-06-12 2012-08-28 The Invention Science Fund I, Llc Methods, compositions, and kits for collecting and detecting oligonucleotides
US8252529B2 (en) * 2008-06-12 2012-08-28 The Invention Science Fund I, Llc Methods for collecting and detecting oligonucleotides
US8614057B2 (en) * 2008-06-12 2013-12-24 The Invention Science Fund I, Llc Methods for collecting and detecting oligonucleotides
GB2463401B (en) 2008-11-12 2014-01-29 Caris Life Sciences Luxembourg Holdings S A R L Characterizing prostate disorders by analysis of microvesicles
WO2011109440A1 (en) 2010-03-01 2011-09-09 Caris Life Sciences Luxembourg Holdings Biomarkers for theranostics
WO2011127219A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
MX349568B (es) 2010-11-30 2017-08-03 Univ Hong Kong Chinese Deteccion de aberraciones geneticas o moleculares asociadas con el cancer.
WO2013052168A2 (en) * 2011-05-26 2013-04-11 Georgetown University Detection aib1-delta 4 protein
US10876152B2 (en) 2012-09-04 2020-12-29 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
GB2533006B (en) 2012-09-04 2017-06-07 Guardant Health Inc Systems and methods to detect copy number variation
US11913065B2 (en) 2012-09-04 2024-02-27 Guardent Health, Inc. Systems and methods to detect rare mutations and copy number variation
US20160040229A1 (en) 2013-08-16 2016-02-11 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
ES2660989T3 (es) 2013-12-28 2018-03-27 Guardant Health, Inc. Métodos y sistemas para detectar variantes genéticas
US11302416B2 (en) 2015-09-02 2022-04-12 Guardant Health Machine learning for somatic single nucleotide variant detection in cell-free tumor nucleic acid sequencing applications
US12540351B2 (en) 2015-09-02 2026-02-03 Guardant Health, Inc. Identification of somatic mutations versus germline variants for cell-free DNA variant calling applications
WO2017106768A1 (en) 2015-12-17 2017-06-22 Guardant Health, Inc. Methods to determine tumor gene copy number by analysis of cell-free dna
US9850523B1 (en) 2016-09-30 2017-12-26 Guardant Health, Inc. Methods for multi-resolution analysis of cell-free nucleic acids
JP6560465B1 (ja) 2016-09-30 2019-08-21 ガーダント ヘルス， インコーポレイテッド 無細胞核酸の多重解像度分析のための方法
US10907211B1 (en) 2017-02-16 2021-02-02 Quantgene Inc. Methods and compositions for detecting cancer biomarkers in bodily fluids
JP7535998B2 (ja) 2018-08-31 2024-08-19 ガーダント ヘルス， インコーポレイテッド マージされたリードおよびマージされないリードに基づいた遺伝的変異体の検出
EP4567131A3 (de) 2019-01-31 2025-09-03 Guardant Health, Inc. Zusammensetzungen und verfahren zur isolierung von zellfreier dna
US11475981B2 (en) 2020-02-18 2022-10-18 Tempus Labs, Inc. Methods and systems for dynamic variant thresholding in a liquid biopsy assay
US11211147B2 (en) 2020-02-18 2021-12-28 Tempus Labs, Inc. Estimation of circulating tumor fraction using off-target reads of targeted-panel sequencing
US11211144B2 (en) 2020-02-18 2021-12-28 Tempus Labs, Inc. Methods and systems for refining copy number variation in a liquid biopsy assay

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4699877A (en) 1982-11-04 1987-10-13 The Regents Of The University Of California Methods and compositions for detecting human tumors
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5274087A (en) 1986-08-13 1993-12-28 Molecular Diagnostics, Inc. cDNA coding for carcinoembryonic antigen (CEA)
DE3717212A1 (de) 1987-05-22 1988-12-08 Viktor Dr Dr Med Balazs Verfahren zur untersuchung einer azellularen biologischen fluessigkeit auf zellulare onkogen-transkripte bzw. deren fragmente
US5124246A (en) 1987-10-15 1992-06-23 Chiron Corporation Nucleic acid multimers and amplified nucleic acid hybridization assays using same
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
US4874858A (en) 1988-03-28 1989-10-17 The B. F. Goodrich Company Triazine-containing multisilane coupling agents for coating glass fibers, for adhesives, and for protective coatings
US4999290A (en) 1988-03-31 1991-03-12 The Board Of Regents, The University Of Texas System Detection of genomic abnormalities with unique aberrant gene transcripts
US5098890A (en) 1988-11-07 1992-03-24 Temple University-Of The Commonwealth System Of Higher Education Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
US5087617A (en) 1989-02-15 1992-02-11 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
WO1990009456A1 (de) 1989-02-16 1990-08-23 Viktor Balazs Malignitätstest (krebs-test) mit verwendung von der polymerasekettenreaktion
US5217889A (en) 1990-10-19 1993-06-08 Roninson Igor B Methods and applications for efficient genetic suppressor elements
US5155018A (en) 1991-07-10 1992-10-13 Hahnemann University Process and kit for isolating and purifying RNA from biological sources
WO1993017127A1 (en) 1992-02-20 1993-09-02 The State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University Boomerand dna amplification
US5300635A (en) 1993-02-01 1994-04-05 University Of Iowa Research Foundation Quaternary amine surfactants and methods of using same in isolation of nucleic acids
DE19681033D2 (de) * 1995-11-16 1999-03-18 Michael W Dahm Verfahren zur Quantifizierung von Tumorzellen in einer Körperflüssigkeit und dazu geeignete Testkits
US5817461A (en) * 1996-01-03 1998-10-06 Hamilton Civic Hospitals Research Development Inc. Methods and compositions for diagnosis of hyperhomocysteinemia
US6607898B1 (en) * 1996-03-26 2003-08-19 Oncomedx, Inc. Method for detection of hTR and hTERT telomerase-associated RNA in plasma or serum
ATE471150T1 (de) 1996-03-26 2010-07-15 Kopreski Michael S Methoden aus plasma oder serum extrahierte extrazelluraere rna zur diagnoseüberwachung oder evaluation von krebs verwenden
EP0932686A2 (de) * 1996-10-01 1999-08-04 Geron Corporation Telomerase reverse-transkriptase
US6610839B1 (en) * 1997-08-14 2003-08-26 Geron Corporation Promoter for telomerase reverse transcriptase
AU733610B2 (en) * 1996-12-20 2001-05-17 Geron Corporation Methods for detecting and inhibiting the RNA component of telomerase
DE19757300A1 (de) * 1997-12-22 1999-06-24 Roche Diagnostics Gmbh Nachweis von Harnblasenkarzinom in einer Urinprobe
DE19804372A1 (de) * 1998-02-04 1999-08-05 Michael W Dr Dr Dahm Verfahren zur quantitativen Bestimmung von Tumorzellen in einer Körperflüssigkeit und dazu geeignete Testkits
AU2682299A (en) * 1998-02-16 1999-08-30 University Of Maryland At Baltimore Telomerase assay of body fluids for cancer screening and assessment of disease stage and prognosis
US6639057B1 (en) * 1998-03-26 2003-10-28 Kyowa Hakko Kogyo Co., Ltd. Monoclonal antibody against human telomerase catalytic subunit

Also Published As

Publication number Publication date
EP1283907A1 (de) 2003-02-19
US7163789B2 (en) 2007-01-16
AU5502101A (en) 2001-12-03
ES2227178T3 (es) 2005-04-01
EP1158055A1 (de) 2001-11-28
WO2001090409A1 (fr) 2001-11-29
DE60105411D1 (de) 2004-10-14
EP1283907B1 (de) 2004-09-08
PT1283907E (pt) 2005-01-31
US20040132019A1 (en) 2004-07-08
DE60105411T2 (de) 2005-09-22

Similar Documents

Publication Publication Date Title
ATE275642T1 (de) Verfahren zur diagnose von krebs
MY133942A (en) Reagent test strip for analyte determination having hemolyzing agent
DE69938662D1 (de) Spurendetektion von analyten mit hilfe artifizieller olfaktometrie
DE60042695D1 (de) Verfahren für den nachweis von erkrankungen
ATE230487T1 (de) Verfahren zur frühen diagnose von carcinomen
NO972006D0 (no) Ny metode for diagnose av sykdommer
DE60029092D1 (de) Verfahren zur detektion von nukleinsäuren, welche auf krebs hinweisen
ATE351923T1 (de) Diagnostische methode zur identifizierung von fötaler dna in einer maternalen probe
DE60041355D1 (de) Verfahren zur detektion von erkrankungen
DE69910007D1 (de) Vorrichtung zum vorhersagen von physiologischen messwerten
EP1281960A3 (de) Methode und Vorrichtung zur Verwendung bei der Bestimmung von Konzentrationen in Analyten
ATE319093T1 (de) Verfahren zur diagnose von leberkrankheit unter verwendung von biochemischen merkmalen
PT1012348E (pt) Deteccao do virus do papiloma humano por pcr e hibridacao reversa tipo-especifica
DE50010710D1 (de) Verfahren zur bestimmung von substanzen mittels der evaneszenzfeldmethode
ATE510927T1 (de) Verfahren zur quantitativen bestimmung von tumorzellen in einer körperflüssigkeit und dazu geeignete testkits
ATE282831T1 (de) Verfahren zur diagnose von sepsis unter bestimmung löslicher cytokeratinfragmente
DE60219809D1 (de) Verbindungen und Verfahren zur Nachweiss von Karzinomen und deren Vorstufen
ES2183399T3 (es) Metodo para la determinacion del funcionamiento del higado.
DE50103030D1 (de) Verfahren zur Diagnose von Sepsis unter Bestimmung von S100B
WO2004109286A3 (en) Methods for detecting and treating cancer using podocalyxin and/or endoglycan
WO2000034504A3 (en) Method of protein removal
ATE429440T1 (de) Formen prostataspezifischer antigene und verfahren zu deren nachweis
ATE135746T1 (de) Enzymatisches verfahren zur bestimmung der analyt-konzentration
DE60309879D1 (de) Verfahren zur Diagnose von Krebs
DE60238055D1 (de) Verfahren zur diagnose einer person mit multipler sklerose

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1283907

Country of ref document: EP